gustavo-frazao-shutterstock-com-patent-

Gustavo Frazao / Shutterstock.com

16 March 2016Americas

PTAB gives green light to four Acorda IPR trials

The Patent Trial and Appeal Board (PTAB) has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic